PE-22-28: Benefits, Dosage and Side Effects in 2026
PE-22-28 is a seven-amino-acid peptide shortened from spadin, a natural fragment of the protein sortilin, designed to block the TREK-1 potassium channel, a target in depression research14. No human study of it has been published; its antidepressant-like effects come from research outside people1.
Other names: mini-spadin, spadin analog. Related: Selank and Semax.
Last updated November 17, 2026 by the Prof. Peptide editorial team
What is PE-22-28?
Where to buy PE-22-28?
PE-22-28 has no prescription product anywhere. Research-grade PE-22-28 is sold by specialty peptide vendors for laboratory use only, with no label behind it. The vendors listed here sell it, each with Prof. Peptide's code. Each vendor name links to its Prof. Peptide page, with the vendor's catalog, testing and shipping details.
Molecular Solutions Peptides: 25% off a first order automatically, plus 10% more with Prof. Peptide’s code, no end date given · checked Nov 6. All current deals
Ion Peptide: Bundle prices up to 45% off, plus 15% with Prof. Peptide’s code, no end date given · checked Nov 17. All current deals
How much does PE-22-28 cost?
PE-22-28's research-grade prices, read from each vendor's own store. The most common PE-22-28 vial is 10 mg, listed by 13 vendors, from $22.09 after the code.
PE-22-28 costs from $2.11 to $6.38 per mg after Prof. Peptide's code, across 17 listings from 17 vendors, with prices as of November 16, 2026; the median listing is $4.50 per mg. Listings are shown lowest first. The price on top is after the PROFPEPTIDE discount code, and the crossed-out price is the vendor's regular price.
Prices as of November 16, 2026
Price trend, vendors' own listed price before any code (median per mg): $4.90 on September 28, 2026 → $5.00 on November 16, 2026. These medians come from the nightly price file, which held 1 listing on the first date and 20 listings on the last, including listings the table above leaves out (vendors excluded, retired or not re-read recently); more vendors were added over the period.
What are PE-22-28's uses and reported benefits?
How does PE-22-28 work?
PE-22-28 is designed to block TREK-1, a potassium channel in nerve cells; blocking it is proposed as a new way to treat depression, separate from serotonin-based drugs14. Its developers report it binds TREK-1 far more tightly than spadin, its parent peptide1. None of this has been measured in people.
How is PE-22-28 dosed?
No label or trial has set a PE-22-28 dose. One clinic publishes a protocol: 100 to 500 mcg intranasally, once a day, for 4 to 12 weeks, sometimes cycled 8 weeks on and 4 off; its page cites no studies6. Another clinic states that no established human therapeutic dose exists7.
Of 6 clinics that publish on PE-22-28, 1 publishes an amount, cited here for its own protocol only. Clinic cautions are under side effects.
Need to calculate a dose?
Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.
Open CalculatorHow is PE-22-28 taken?
Clinics administer PE-22-28 intranasally, and some by subcutaneous injection at similar amounts67. No approved label sets out a route. The peptide dosage calculator works out how much bacteriostatic water to add to a research-grade vial and how many syringe units a given amount takes. It does not set a dose.
What are the side effects of PE-22-28?
PE-22-28's side effects in people are unknown: no human safety data are published. Its developers describe spadin, its parent peptide, as not inducing side effects in their research outside people2, but that does not show safety in people, and no adverse-event report in people has been published.
The clinic that publishes a protocol lists mild nasal irritation, headache, passing mood changes, nausea and tiredness. It warns never to add PE-22-28 to an SSRI, SNRI or MAOI without a clinician's evaluation, because of the risk of serotonin syndrome, and says pregnancy and nursing have insufficient safety data6.
Is PE-22-28 legal?
PE-22-28 is not approved for use in people anywhere, and clinics state that it is not legally available as a prescription medication7; one clinic describes it as a wellness compound, not a prescription antidepressant6. Research-grade vials are a different product, covered last.
Legal status
- FDA: not approved. PE-22-28 does not appear on FDA's bulk-substance safety-risk page.
- Research-grade vials: sold for laboratory use only, not for human use; a research-use label does not make a vial an approved or prescribed product.
What do human studies show about PE-22-28?
What does animal and lab research show about PE-22-28?
PE-22-28 was designed and tested in mice and cells: it blocked TREK-1 several hundred times more potently than spadin, reduced depression-like behavior in standard mouse tests, spurred new neurons, and acted for up to 23 hours against spadin's 71. Mini-spadin also aided stroke recovery in mice3. Animal results do not show the same in people.
PE-22-28 FAQ
Has PE-22-28 been studied in people?
PE-22-28 has never been given to people in a published study. Its antidepressant-like effects, and its longer action than spadin, come from research outside people by the group that designed it1. No human data exist on its dose, route, safety or effect on mood. See What do human studies show about PE-22-28?
Is PE-22-28 legal?
PE-22-28 is not approved for use in people anywhere, and clinics state that it is not legally available as a prescription medication7; one clinic describes it as a wellness compound, not a prescription antidepressant6. Research-grade vials are sold for laboratory use only. See Is PE-22-28 legal?
Where can I buy PE-22-28?
PE-22-28 is not approved for use in people, so no prescription product exists. Research-grade material is sold by vendors for laboratory use only. Where to buy PE-22-28? lists vendors with Prof. Peptide's code, and How much does PE-22-28 cost? compares prices. The verified discount codes page lists every vendor with a code.
References
Show all references
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant ActivityAnimal and labDjillani A, Pietri M, Moreno S, et al. Front Pharmacol. 2017. Abstract read November 3, 2026.Key finding: PE 22-28 (7 amino acids): TREK-1 IC50 0.12 nM vs 40–60 nM for spadin in hTREK-1/HEK cells; reduced immobility (forced swim) and feeding latency (novelty-suppressed feeding, 4 days) in mice; neurogenesis; action up to 23 h vs 7 h for spadin.PubMed 28955242 →DOI →
- Retroinverso analogs of spadin display increased antidepressant effectsAnimal studyVeyssiere J, Moha Ou Maati H, Mazella J, et al. Psychopharmacology (Berl). 2015. Abstract read November 3, 2026.PubMed 25080852 →DOI →
- First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptidesAnimal studyPietri M, Djillani A, Mazella J, et al. Neuropharmacology. 2019. Abstract read November 3, 2026.PubMed 31325429 →DOI →
- Fighting against depression with TREK-1 blockers: Past and future. A focus on spadinReviewDjillani A, Pietri M, Mazella J, Heurteaux C, Borsotto M. Pharmacol Ther. 2019. Abstract read November 3, 2026.PubMed 30291907 →DOI →
- The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1ReviewMazella J, Borsotto M, Heurteaux C. Front Pharmacol. 2018. Abstract read November 3, 2026.PubMed 30670975 →DOI →
- PE-22-28 peptide 2026: benefits, dosage, side effects, protocolClinicInjectCo Medical Aesthetics, Texas. Article by its VP of Clinical, May 15, 2026; read November 5, 2026. Cited for its own protocol only; the page cites no studies.Key finding: "Intranasal delivery: typically 100-500 mcg per administration"; "Once daily is the most common frequency"; "4-12 weeks initial protocol"; cycling "8 weeks on, 4 weeks off"; SSRIs, SNRIs, MAOIs: "Risk of serotonin syndrome"; "Pregnancy and nursing: insufficient safety data"; "large-scale long-term human safety studies do not yet exist"; "not a prescription antidepressant".injectco.com →
- PE-22-28ClinicParagon Sports Medicine. Peptide library page; read November 5, 2026.Key finding: "No established human therapeutic dose exists because there are no completed human trials."; "Not legally available as prescription medication"; route parenteral or intranasal.paragonsportsmedicine.com →
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Have a question about PE-22-28? Send us an email
Checked and updated



